Colorectal Cancer
Copyright ©The Author(s) 2003.
World J Gastroenterol. May 15, 2003; 9(5): 965-969
Published online May 15, 2003. doi: 10.3748/wjg.v9.i5.965
Table 1 Cell growth inhibition of recombinant adenovirus on HT29 cell
GroupOD (-x±s)Cell growth inhibition rates (%)
Ad/GT-TRAIL0.57 ± 0.12ac52.5
Ad/GT-Bax0.84 ± 0.08a30.3
Ad/GT-LacZ1.07 ± 0.1310.5
PBS1.20 ± 0.170.0
Table 2 Cell growth inhibition of recombinant adenovirus on HT29 cell when combined with Ad/PGK-GV16
GroupOD (-x±s)Cell growth inhibition rates (%)
Ad/GT-TRAIL + Ad/PGK-GV160.18 ± 0.03ac85.2
Ad/GT-Bax + Ad/PGK-GV160.46 ± 0.09a61.5
Ad/GT-LacZ + Ad/PGK-GV161.05 ± 0.0712.1
PBS1.20 ± 0.170.0
Table 3 The percentage of apoptotic cells of recombinant adenovirus on HT29 cell after 5 d treatment
GroupThe percentage of apoptotic cells (%, -x±s)
Ad/GT-TRAIL16.50 ± 1.13a
Ad/GT-Bax14.70 ± 0.46a
Ad/GT-LacZ7.45 ± 0.75
PBS6.15 ± 0.23
Table 4 The percentage of apoptotic cells of recombinant adenovirus on HT29 cell when combined with Ad/PGK-GV16 after 5 d treatment
GroupThe percentage of apoptotic cells (%, -x±s)
Ad/GT-TRAIL + Ad/PGK-GV1635.90 ± 1.32a
Ad/GT-Bax + Ad/PGK-GV1629.00 ± 1.66a
Ad/GT-LacZ + Ad/PGK-GV1611.23 ± 1.14
PBS6.15 ± 0.23